Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin with PEGPH20 in HER2-negative High-HA Metastatic Breast Cancer
NCT02753595Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2016
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegvorhyaluronidase alfa in breast cancer (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Recommended Phase 2 Dose and Objective Response Rate. Started Jul 2016; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02753595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753595.